MannKind | MNKD - Current Liabilities


MannKind reported $171.03M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Adma Biologics USD 69.54M 13.05M Dec/2025
BioCryst Pharmaceuticals USD 196.07M 5.83M Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
MacroGenics USD 43.11M 1.36M Dec/2025
MannKind USD 171.03M 61.9M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Minerva Neurosciences USD 2.29M 381K Dec/2025
Novavax USD 459.95M 30.08M Dec/2025
Novo Nordisk DKK 32.79B 203.33B Jun/2025
Pfizer USD 36.6B 1.13B Sep/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Xencor USD 95.91M 9.42M Dec/2025